426 related articles for article (PubMed ID: 29516287)
1. What Is the Evidence for Treat-to-Target Serum Urate in Gout?
Bursill D; Dalbeth N
Curr Rheumatol Rep; 2018 Mar; 20(3):11. PubMed ID: 29516287
[TBL] [Abstract][Full Text] [Related]
2. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
Graham GG; Stocker SL; Kannangara DRW; Day RO
Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
[TBL] [Abstract][Full Text] [Related]
3. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Corbett EJM; Pentony P; McGill NW
Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
Doherty M; Jenkins W; Richardson H; Sarmanova A; Abhishek A; Ashton D; Barclay C; Doherty S; Duley L; Hatton R; Rees F; Stevenson M; Zhang W
Lancet; 2018 Oct; 392(10156):1403-1412. PubMed ID: 30343856
[TBL] [Abstract][Full Text] [Related]
5. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.
Soskind R; Abazia DT; Bridgeman MB
Expert Opin Pharmacother; 2017 Aug; 18(11):1115-1125. PubMed ID: 28658988
[TBL] [Abstract][Full Text] [Related]
6. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
[TBL] [Abstract][Full Text] [Related]
7. Management of Gout in a Hospital Setting: A Lost Opportunity.
Wright S; Chapman PT; Frampton C; O'Donnell JL; Raja R; Stamp LK
J Rheumatol; 2017 Oct; 44(10):1493-1498. PubMed ID: 28765252
[TBL] [Abstract][Full Text] [Related]
8. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
[TBL] [Abstract][Full Text] [Related]
9. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
[TBL] [Abstract][Full Text] [Related]
10. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
Mandell BF; Yeo AE; Lipsky PE
Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
[TBL] [Abstract][Full Text] [Related]
11. Gout.
Dalbeth N; Choi HK; Joosten LAB; Khanna PP; Matsuo H; Perez-Ruiz F; Stamp LK
Nat Rev Dis Primers; 2019 Sep; 5(1):69. PubMed ID: 31558729
[TBL] [Abstract][Full Text] [Related]
12. Pegloticase for treating refractory chronic gout.
George RL; Sundy JS
Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
[TBL] [Abstract][Full Text] [Related]
13. Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.
Beslon V; Moreau P; Maruani A; Maisonneuve H; Giraudeau B; Fournier JP
J Gen Intern Med; 2018 Mar; 33(3):358-366. PubMed ID: 29204974
[TBL] [Abstract][Full Text] [Related]
14. Evaluation and treatment of gout as a chronic disease.
Perez-Ruiz F; Herrero-Beites AM
Adv Ther; 2012 Nov; 29(11):935-46. PubMed ID: 23104464
[TBL] [Abstract][Full Text] [Related]
15. Chronic gout: Barriers to effective management.
Rogenmoser S; Arnold MH
Aust J Gen Pract; 2018 Jun; 47(6):351-356. PubMed ID: 29966174
[TBL] [Abstract][Full Text] [Related]
16. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
17. Current and future therapies for gout.
Pascart T; Richette P
Expert Opin Pharmacother; 2017 Aug; 18(12):1201-1211. PubMed ID: 28689430
[TBL] [Abstract][Full Text] [Related]
18. Critical appraisal of serum urate targets in the management of gout.
Stamp LK; Dalbeth N
Nat Rev Rheumatol; 2022 Oct; 18(10):603-609. PubMed ID: 35974164
[TBL] [Abstract][Full Text] [Related]
19. Gout.
Dalbeth N; Merriman TR; Stamp LK
Lancet; 2016 Oct; 388(10055):2039-2052. PubMed ID: 27112094
[TBL] [Abstract][Full Text] [Related]
20. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]